Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14920940 | 0.81 | MAPT (0.48) | GAAMAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL6863197 | 0.78 | KDM4E (0.33) | GAAMAPTALDH1A1RAB9ALMNA | |
| SCHEMBL14934959 | 0.75 | SMN1; SMN2 (0.44) | GAAMAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL4581245 | 0.74 | LMNA (0.59) | GAAMAPTALDH1A1ALOX5MEN1 | |
| SCHEMBL7653658 | 0.74 | KDM4E (0.44) | GAAALDH1A1 | |
| SCHEMBL6865356 | 0.74 | GAA (0.51) | GAAMAPTALDH1A1ALOX5MEN1 | |
| SCHEMBL28060524 | 0.74 | ICMT (0.56) | MAPTALDH1A1RAB9AALOX5MEN1 | |
| SCHEMBL11227972 | 0.73 | GAA (0.45) | GAAMAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL31148959 | 0.73 | SMN1; SMN2 (0.57) | GAAMAPTALDH1A1ALOX5MEN1 | |
| SCHEMBL31148954 | 0.73 | SMN1; SMN2 (0.57) | GAAMAPTALDH1A1ALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1131280-B1 | PREPARATION OF 5-AMINO-ISOPHTHALAMIDES | AMERSHAM HEALTH AS (NO) | 2004-08-11 | — | — | EP | disclosed |
| US-6441235-B1 | DI-LOWER-ALKYL-5-NITROISOPHTHALATE REACTS WITH A DIHYDROXY-MONOALKYLAMINE IN THE PRESENCE OF A BASIC CATALYST AND THEN CATALYLYTICALLY HYDROGENATED, WITHOUT ISOLATING THE 5-NITRO-N,N'-BIS(R)ISOPHTHALAMIDE INTERMEDIATE | AMERSHA, HEALTH AS (NO) | 2002-08-27 | — | — | US | disclosed |
| US-20020095053-A1 | Preparation of 5-amino-isophthalamides | GE HEALTHCARE AS (NO) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095053-A1 | Preparation of 5-amino-isophthalamides | DNPH1, DDAH1, DOHH | GAA 4260/4885MAPT 4168/4885ALDH1A1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.